<DOC>
	<DOCNO>NCT00236899</DOCNO>
	<brief_summary>Multi-center , randomize Phase III study . 4 arm . 360 Patient enroll . Purpose evaluate time progression disease ( PD ) .</brief_summary>
	<brief_title>Phase III Study Two Different Schedules ( Weekly Tri-weekly ) Combination Gemcitabine Two Taxanes MBC</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologic diagnosis metastatic breast cancer ( MBC ) . Prior neoadjuvant adjuvant taxanes regimen allow â‰¥12 month since completion regimen . Relapsing receive one adjuvant/neoadjuvant chemotherapy contain anthracycline clinically contraindicate . Patients measurable disease . Previous hormonal therapy adjuvant set metastatic disease . Previous chemotherapy MBC Previous chemotherapy gemcitabine set disease Patient candidable treatment trastuzumab .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>